Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**(5Z)-7-oxozeaenol** is a resorcylic acid lactone of fungal origin, specifically isolated from *Curvularia* species, and acts as a highly potent, selective, irreversible, and ATP-competitive inhibitor of transforming growth factor-β-activated kinase 1 (TAK1, a MAPKKK). It exhibits strong anti-inflammatory and cytotoxic properties, inhibits the NF-κB signaling pathway, and blocks the production of pro-inflammatory cytokines (IL-17A, IFN-γ, TNF-α, IL-6). It also inhibits other kinases such as VEGF receptor 2 (VEGFR2) and PDGFRβ, but with less potency. (5Z)-7-oxozeaenol has demonstrated efficacy in animal models of CNS autoimmune diseases (such as experimental autoimmune encephalomyelitis, EAE—a model of multiple sclerosis), alleviating symptoms by reducing CNS inflammation, demyelination, and microglial activation[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5Z)-7-oxozeaenol.